Seven out of 67 children who were given bluebird bio’s (NASDAQ:BLUE) gene therapy Skysona during clinical trials ended up ...

Whilst the events do not outline any new safety risks, the data gives a new understanding of the link between oncogenesis and ...

Pfizer shared that the combination of its drugs Talzenna and Xtandi extended survival in men with metastatic ...

A Bluebird Bio gene therapy has helped children with a devastating neurological disorder, but seven have developed blood ...

The recent publication in the New England Journal of Medicine highlighting an increased incidence of hematologic cancers in patients treated with Bluebird Bio’s Skysona product has raised concerns.

Seven young boys given Bluebird's Skysona later developed blood cancers, findings that could shape how doctors balance the gene therapy’s risks against its benefit.

Another restructuring is underway at bluebird bio Inc., this time with plans to lay off about 25% of the Somerville company’s ...

Bluebird bio announces restructuring plans to reduce costs by 20% and achieve cash flow break-even by late 2025. The ...

(BLUE) plans to reduce workforce by 25%, optimize cost structure, focus on commercial launches, and aim for cash flow ...

The company has not yet seen the financial payoff from its scientific breakthroughs — and it says it is continuing to lose ...

About a month after reporting it’s had a tough time starting enough patients on its treatments, bluebird bio announced it ...

As part of the restructuring, Bluebird plans to focus further on the ongoing commercial launches of LYFGENIA, ZYNTEGLO, and SKYSONA to enable continued launch acceleration while the company ...